Cell line · CVCL_6298
Papers53
1 more article gives this line's RRID in its Methods without naming the line nearby, so it is not listed.
1 to 20 of 53
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| PubMed 42997835 | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| SUMOylation-Dependent Repression of BIRC7 by DNMT3a Suppresses Papillary Thyroid Carcinoma Progression. | Cell Biochem Funct | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The role of miR-335-5p in the redifferentiation of BRAF p.V600E thyroid cancers. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Unveiling ER-Phagy Receptors in Thyroid Cancer: A Combined Approach of Public Data Mining and In Vitro Validation. | Clin Med Insights Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Loss of CSE couples with BRAF V600E to fuel thyroid cancer metastatic progression through zinc-dependent activation of the EMT machinery. | J Exp Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Modulation of chemokine secretion and oxidative stress in vitro in thyroid cells after exposure to thiocyanate, nitrate, or perchlorate. | Front Endocrinol (Lausanne) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Sunitinib enhances cuproptosis induced by copper ionophores via ROS-ATF3-SLC31A1 axis in thyroid Carcinoma. | Cell Death Dis | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Combination of Lenvatinib and Antibiotics: A Potential Approach to Enhance Sensitivity in Differentiated Thyroid Cancer. | Int J Cancer | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Inhibition of ATM reverses radioiodine resistance in differentiated thyroid cancer via genotoxic stress amplification. | J Transl Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Bisphenol A Induces DNA Damage and Differential Cytotoxicity in Thyroid Cells: High-Dose Effects Challenge Regulatory Thresholds. | J Appl Toxicol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Dual targeting of RET and SRC synergizes in RET fusion-positive cancer cells. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting EZH2 reverses thyroid cell dedifferentiation and enhances iodide uptake in anaplastic thyroid cancer. | FEBS Lett | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Immunomodulatory effects of lenvatinib in patients with advanced thyroid cancer. | Cancer Immunol Immunother | 2025 | Its Methods give the RRID and name the line | PubMed | |
| TSH Ligand-Based CAR-T Cell Effectively Eradicates TSHR-Positive Thyroid Cancer with Favorable Safety Profile. | Adv Sci (Weinh) | 2025 | Its Methods give the RRID and name the line | PubMed | |
| AURKB and PI3K/AKT/mTOR pathways converge to regulate TERT expression. | iScience | 2025 | Its Methods give the RRID and name the line | PubMed | |
| P4HA2 promotes the progression of papillary thyroid cancer by enhancing degradation of IκBα to activate NF-κB signaling pathway. | Cancer Cell Int | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Pharmacodynamics of huaier aqueous extract against papillary thyroid carcinoma in vivo and in vitro. | Integr Cancer Ther | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Single-cell RNA-sequencing and spatial transcriptomic analysis reveal a distinct population of APOE- cells yielding pathological lymph node metastasis in papillary thyroid cancer. | Clin Transl Med | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Low-dose ionizing radiation-induced RET/PTC1 rearrangement via the non-homologous end joining pathway to drive thyroid cancer. | MedComm (2020) | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Exploring the Therapeutic Potential of Extracellular Vesicles Derived from Human Immature Dental Pulp Cells on Papillary Thyroid Cancer. | Int J Mol Sci | 2024 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_6298/papers